All In Biotech

Drug Trial Radar · NCT06091254

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 822 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

822

Planned (sponsor's estimate)

Start

Dec 12, 2023

Primary completion

Feb 29, 2028

Study completion Nov 30, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects quality of life and ability to complete routine daily activities.

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • OdronextamabDrug

    Administered per the protocol

  • RituximabDrug

    Administered per the protocol

  • CyclophosphamideDrug

    Administered per the protocol as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy

  • DoxorubicinDrug

    Administered per the protocol as part of CHOP chemotherapy

  • VincristineDrug

    Administered per the protocol as part of CHOP, and CVP chemotherapy

  • Prednisone/prednisoloneDrug

    Administered per the protocol as part of CVP chemotherapy

  • BendamustineDrug

    Administered per the protocol as part of chemotherapy (Rituximab-Bendamustine)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs) for odronextamabTime frame: Up to 35 days
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs) of odronextamabTime frame: Up to 2 years
  3. Severity of TEAEs of odronextamabTime frame: Up to 2 years
  4. Complete Response at 30 months (CR30) as assessed by independent central reviewTime frame: Up to 30 months

Locations

190 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • UC Irvine Health

    Orange, California · Withdrawn

  • Investigative Clinical Research of Indiana

    Noblesville, Indiana · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Completed

  • Icahn School of Medicine at Mt Sinai

    New York, New York · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • Clinical Research Alliance Inc

    Westbury, New York · Withdrawn

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Center for Oncology and Blood Disorders

    Houston, Texas · Recruiting

  • HOPE Cancer Center of East Texas

    Tyler, Texas · Withdrawn

  • Huntsman Cancer Institute - Oncology Division

    Salt Lake City, Utah · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Withdrawn

  • Prohealth Care Inc

    Waukesha, Wisconsin · Withdrawn

  • Ingham Institute

    Liverpool, New South Wales, Australia · Recruiting

  • Icon Cancer Centre - Wesley

    Auchenflower, Queensland, Australia · Completed

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Epworth Freemasons

    East Melbourne, Victoria, Australia · Recruiting

  • Alfred Hospital and Monash University

    Melbourne, Victoria, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Melbourne, Victoria, Australia · Recruiting

  • Ordensklinikum Linz Gmbh, Elisabethinen

    Linz, Austria · Recruiting

  • Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III

    Salzburg, Austria · Recruiting

  • Medical University of Vienna

    Vienna, Austria · Recruiting

  • Hanusch Krankenhaus

    Vienna, Austria · Recruiting

  • Ordensklinikum Linz

    Linz, Osterreich, Austria · Recruiting

  • Ziekenhuis Netwerk Antwerpen Stuivenberg

    Antwerp, Belgium · Withdrawn

  • Institut Jules Bordet

    Brussels, Belgium · Withdrawn

  • AZ St.-Elisabeth Herentals vzw

    Herentals, Antwerp, Belgium · Withdrawn

  • Hopital De Jolimont

    La Louvière, Hainaut, Belgium · Withdrawn

  • Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium · Withdrawn

  • Instituto DOr de Pesquisa e Ensino Df Star

    Brasília, Brazil · Recruiting

  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil · Withdrawn

  • Instituto Americas

    Rio de Janeiro, Brazil · Recruiting

Showing 40 of 190 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.